A Phase 3, Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Failed to Respond to Steroid Treatment for Acute GVHD

Acute graft-versus-host disease (aGVHD) is a major obstacle to the overall success of allogeneic hematopoietic stem cell transplantation (HSCT). Although the incidence of aGVHD varies across transplant type and donor sources, severe aGVHD (determined by grade C/D, visceral organ and/or multi-organ involvement, or high risk stratification) is associated with the highest risk of primary treatment failure and highest transplant related mortality [1,2]. Mortality can reach as high as 90% in adults and children who fail to respond to initial steroid therapy [2 –5].

Source: Biology of Blood and Marrow Transplantation - January 31, 2020 Category: Hematology Authors: Joanne Kurtzberg, Hisham Abdel-Azim, Paul Carpenter, Sonali Chaudhury, Biljana Horn, Kris Mahadeo, Eneida Nemecek, Steven Neudorf, Vinod Prasad, Susan Prockop, Troy Quigg, Prakash Satwani, Annie Cheng, Elizabeth Burke, Jack Hayes, Donna Skerrett, for the Source Type: research